Results 241 to 250 of about 1,659,411 (286)
Some of the next articles are maybe not open access.
Journal of Clinical Pharmacy and Therapeutics, 2016
Patients with schizophrenia are most commonly treated with antipsychotic medications, often with the addition of anxiolytics. This study used an oral moisture meter to evaluate xerostomia in patients with schizophrenia taking typical and atypical antipsychotics, anxiolytics and non-psychotropic medications.Patients diagnosed with schizophrenia ...
A, Okamoto +4 more
openaire +2 more sources
Patients with schizophrenia are most commonly treated with antipsychotic medications, often with the addition of anxiolytics. This study used an oral moisture meter to evaluate xerostomia in patients with schizophrenia taking typical and atypical antipsychotics, anxiolytics and non-psychotropic medications.Patients diagnosed with schizophrenia ...
A, Okamoto +4 more
openaire +2 more sources
Systemic Versus Oral and Gastrointestinal Metering of Fluid Intake
1975More than one and a half centuries after Dupuytren showed that the intravenous (I.V.) injection of water into a thirsty dog prevented drinking, the respective roles of systemic and of oro-gastrointestinal factors in the control of water intake are still disputed.
S. Nicolaïdis, N. Rowland
openaire +1 more source
The APPEA Journal, 2023
Presented on Tuesday 16 May: Session 2 The accuracy of ultrasonic metering technology has advanced to a level that it is now the technology of choice in many custody transfer and fiscal applications. With meters capable of meeting the accuracy requirements of these applications when initially calibrated, end-user attention has moved ...
openaire +1 more source
Presented on Tuesday 16 May: Session 2 The accuracy of ultrasonic metering technology has advanced to a level that it is now the technology of choice in many custody transfer and fiscal applications. With meters capable of meeting the accuracy requirements of these applications when initially calibrated, end-user attention has moved ...
openaire +1 more source
Annals of Allergy, Asthma & Immunology, 2000
After inhalation of a glucocorticoid from a meter dose inhaler (MDI), a certain portion of the delivered dose is deposited in the lungs, and the remainder is deposited in the oropharynx.To examine the absolute bioavailability of flunisolide given orally via metered dose inhaler, and metered dose inhaler with a commercially available spacer device as ...
G R, Dickens +7 more
openaire +2 more sources
After inhalation of a glucocorticoid from a meter dose inhaler (MDI), a certain portion of the delivered dose is deposited in the lungs, and the remainder is deposited in the oropharynx.To examine the absolute bioavailability of flunisolide given orally via metered dose inhaler, and metered dose inhaler with a commercially available spacer device as ...
G R, Dickens +7 more
openaire +2 more sources
Biopharmaceutics & Drug Disposition, 1998
3M has formulated a new chlorofluorocarbon-free (CFC-free) beclomethasone dipropionate (BDP) metered-dose inhaler (MDI) with the use of the propellant HFA-134a (HFA). Lung deposition studies demonstrated that the HFA BDP MDI delivers to the lungs approximately 56% of the BDP dose (ex-adaptor), a substantially higher percentage than the 5-30% delivered ...
I, Soria +4 more
openaire +2 more sources
3M has formulated a new chlorofluorocarbon-free (CFC-free) beclomethasone dipropionate (BDP) metered-dose inhaler (MDI) with the use of the propellant HFA-134a (HFA). Lung deposition studies demonstrated that the HFA BDP MDI delivers to the lungs approximately 56% of the BDP dose (ex-adaptor), a substantially higher percentage than the 5-30% delivered ...
I, Soria +4 more
openaire +2 more sources
Clinical Therapeutics, 2002
Acute exacerbations of chronic obstructive pulmonary disease (COPD) are managed with increased doses or frequency of the patient's existing bronchodilator therapy. The use of formoterol in the treatment of mild acute exacerbations of COPD has been suggested; however, a comparison of cumulative doses of formoterol with salbutamol, the gold standard ...
CAZZOLA M +6 more
openaire +3 more sources
Acute exacerbations of chronic obstructive pulmonary disease (COPD) are managed with increased doses or frequency of the patient's existing bronchodilator therapy. The use of formoterol in the treatment of mild acute exacerbations of COPD has been suggested; however, a comparison of cumulative doses of formoterol with salbutamol, the gold standard ...
CAZZOLA M +6 more
openaire +3 more sources
Respiratory Care, 2002
OBJECTIVE: Compare the therapeutic efficacy of an oral/metered-dose inhaler (oral/MDI) regimen to an intravenous/nebulizer (I.V./neb) regimen of methylprednisolone, cefuroxime, and inhaled albuterol and ipratropium bromide in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD).
Sean P, Shortall +5 more
openaire +2 more sources
OBJECTIVE: Compare the therapeutic efficacy of an oral/metered-dose inhaler (oral/MDI) regimen to an intravenous/nebulizer (I.V./neb) regimen of methylprednisolone, cefuroxime, and inhaled albuterol and ipratropium bromide in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD).
Sean P, Shortall +5 more
openaire +2 more sources
Clinical Pharmacology in Drug Development, 2014
AbstractA fixed‐dose combination (FDC) containing mometasone furoate (MF) and formoterol fumarate (F) in a pressurized metered dose inhaler (MDI) is approved for asthma and is being developed for COPD. This randomized, open‐label, 4‐period crossover study compared single‐dose pharmacokinetics of MF 800 µg; F 20 µg; MF 800 µg + F 20 µg coadministered ...
Teddy, Kosoglou +5 more
openaire +2 more sources
AbstractA fixed‐dose combination (FDC) containing mometasone furoate (MF) and formoterol fumarate (F) in a pressurized metered dose inhaler (MDI) is approved for asthma and is being developed for COPD. This randomized, open‐label, 4‐period crossover study compared single‐dose pharmacokinetics of MF 800 µg; F 20 µg; MF 800 µg + F 20 µg coadministered ...
Teddy, Kosoglou +5 more
openaire +2 more sources
Airway Pharmacology and Treatment, 2017
Background: AZD7594 is an inhaled, nonsteroidal, potent, and selective modulator of the glucocorticoid receptor (GR). It is being developed for once-daily treatment of chronic obstructive pulmonary disease and asthma, either alone or in combination with a bronchodilator.
Yingxue Chen +7 more
openaire +1 more source
Background: AZD7594 is an inhaled, nonsteroidal, potent, and selective modulator of the glucocorticoid receptor (GR). It is being developed for once-daily treatment of chronic obstructive pulmonary disease and asthma, either alone or in combination with a bronchodilator.
Yingxue Chen +7 more
openaire +1 more source
Clinical Pharmacology in Drug Development, 2014
AbstractPurposeThis randomized, open‐label, multiple‐dose, two‐period, crossover study compared the systemic bioavailability of mometasone furoate (MF) administered from a metered‐dose inhaler containing MF and formoterol fumarate (F) (MF/F‐MDI) versus MF administered from a single‐ingredient dry‐powder inhaler (MF‐DPI).MethodsHealthy, non‐smoking ...
Teddy, Kosoglou +4 more
openaire +2 more sources
AbstractPurposeThis randomized, open‐label, multiple‐dose, two‐period, crossover study compared the systemic bioavailability of mometasone furoate (MF) administered from a metered‐dose inhaler containing MF and formoterol fumarate (F) (MF/F‐MDI) versus MF administered from a single‐ingredient dry‐powder inhaler (MF‐DPI).MethodsHealthy, non‐smoking ...
Teddy, Kosoglou +4 more
openaire +2 more sources